Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity.
Antibiotics, Antineoplastic
/ adverse effects
Cell Line
Cell Proliferation
/ drug effects
Dose-Response Relationship, Drug
Doxorubicin
/ adverse effects
Drug Design
Drug Resistance, Neoplasm
/ drug effects
Drug Screening Assays, Antitumor
Humans
Molecular Structure
Peptides, Cyclic
/ chemical synthesis
Structure-Activity Relationship
Cancer
Delivery
Doxorubicin
Peptide
Resistance
Toxicity
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
15 Dec 2021
15 Dec 2021
Historique:
received:
12
06
2021
revised:
19
08
2021
accepted:
05
09
2021
pubmed:
20
9
2021
medline:
27
1
2022
entrez:
19
9
2021
Statut:
ppublish
Résumé
Doxorubicin (Dox) is used for breast cancer, leukemia, and lymphoma treatment as an effective chemotherapeutic agent. However, Dox use is restricted due to inherent and acquired resistance and an 8-fold increase in the risk of potentially fatal cardiotoxicity. Hybrid cyclic-linear peptide [R
Identifiants
pubmed: 34537446
pii: S0223-5234(21)00685-1
doi: 10.1016/j.ejmech.2021.113836
pii:
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Peptides, Cyclic
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113836Informations de copyright
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.